<DOC>
	<DOCNO>NCT01849770</DOCNO>
	<brief_summary>The purpose research find mexiletine safe effective people Amyotrophic Lateral Sclerosis ( ALS ) . In trial , participant take either 300 milligram per day mexiletine , 900 milligram per day mexiletine placebo ( non-active study drug ) . The safety efficacy dos compare see one dose well .</brief_summary>
	<brief_title>Mexiletine Sporadic Amyotrophic Lateral Sclerosis ( SALS )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disorder affect primarily motor neuron , treatment design slow arrest progression remain lack . Mexiletine use-dependent sodium channel blocker FDA-approved decade treatment cardiac arrhythmia recently treat neuropathic pain diabetic polyneuropathy . Mexiletine show also protective neuron follow spinal cord , head injury , cerebral ischemia , largely block excitotoxicity . Based previous study , mexiletine appear penetrate central nervous system concentration sufficient confer significant protection . Recent unpublished study laboratory Dr. Robert Brown University Massachusetts also demonstrate mexiletine ingestion mouse genetically engineer express high level mutant cytosolic copper-zinc superoxide dismutase-1 ( SOD1 ) transgene prolongs survival animal . As mexiletine already FDA-approval anti-arrhythmic agent , much know pharmacology safety drug non-ALS patient . We anticipate exclude subject know history cardiac disease know neuroprotectant property medication , mexiletine good choice study ALS clinical trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>Sporadic Amyotrophic Lateral Sclerosis ( SALS ) diagnose possible , laboratorysupported probable , probable , definite ALS define revise El Escorial criterion . Age 18 year old . Disease duration ≤ 36 month ALS symptom onset . Capable provide informed consent follow trial procedure . Subjects must take riluzole least 30 day 50 milligram twice daily dose riluzole least 60 day prior randomization ( riluzolenaïve subject permit study ) . Subjects must take medication muscle cramp cyclobenzaprine , baclofen , carisoprodol , methocarbamol , least 30 day prior randomization stable dose least 60 day prior randomization . Geographic accessibility site . Women must become pregnant duration study must willing use two contraceptive therapy negative pregnancy test throughout course study . Slow vital capacity ( SVC ) measure great equal 50 % predicted gender , height , age screen visit . Subjects medically able undergo lumbar puncture ( LP ) determine investigator ( example , bleed disorder , allergy local anesthetic , skin infection near LP site , evidence high intracranial pressure ) . Must able swallow capsule throughout course study , accord Principal Investigator ( PI ) judgment . Must caregiver assist dispense study drug . Invasive ventilator dependence , tracheostomy . Creatinine level great 1.5 milligram/deciliter . Serum glutamic oxaloacetic transaminase ( aspartate transaminase ) / serum glutamic pyruvic transaminase ( alanine aminotransferase ) great 3 time upper limit normal screening . History known sensitivity intolerability mexiletine lidocaine . Any history either substance abuse within past year , unstable psychiatric disease , cognitive impairment , dementia . Clinically significant conduction abnormality electrocardiogram know history cardiac arrhythmia . Known history epilepsy . Known history congestive heart failure ( CHF ) history myocardial infarction within past 24 month . Use mexiletine 60 day prior Baseline Visit . Exposure experimental agent ( offlabel use investigational ) include high dose creatine ( great 10 gram day ) within 30 day prior Baseline Visit . Use amiodarone , flecainide , duloxetine , tizanidine , clozapine . Pregnant woman woman currently breastfeed . Placement Diaphragm Pacing System ( DPS ) device le 60 day prior Baseline Visit . Planned DPS device implantation Baseline Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>SALS</keyword>
	<keyword>Mexiletine</keyword>
	<keyword>Safety</keyword>
</DOC>